Bruker (BRKR)
(Delayed Data from NSDQ)
$63.54 USD
-2.34 (-3.55%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $63.56 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.54 USD
-2.34 (-3.55%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $63.56 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Walt Disney (DIS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Disney's (DIS) fiscal Q1 results are expected to reflect stalled Disney+ subscriber growth rate amid stiff competition.
Perion Network (PERI) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Perion Network's (PERI) fourth-quarter 2022 performance is expected to have benefited from robust advertiser demand for video and CTV as well as SORT solutions.
onsemi's (ON) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
onsemi's (ON) fourth-quarter 2022 performance reflects strong demand for intelligent and sensing products across automotive and industrial end markets.
Digital Turbine (APPS) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Digital Turbine's (APPS) fiscal third-quarter earnings are expected to have suffered from macroeconomic challenges including high inflation, which has hurt ad revenue business.
Axcelis (ACLS) to Post Q4 Earnings: Key Factors to Note
by Zacks Equity Research
Axcelis's (ACLS) fourth-quarter performance is likely to have benefited from increased demand for the Purion suite of products.
Skyworks (SWKS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Skyworks' (SWKS) first-quarter fiscal 2023 results are likely to reflect gains from momentum witnessed in 5G and Wi-Fi 6 solutions amid supply chain constraints.
Microchip (MCHP) Q3 Earnings Top Estimates, Sales Rise Y/Y
by Zacks Equity Research
Microchip's (MCHP) third-quarter fiscal 2023 results reflect continued momentum in the microcontroller business despite the weaker business environment in China.
onsemi (ON) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
onsemi's (ON) fourth-quarter 2022 results are likely to reflect the benefits of the key megatrends such as EVs, energy infrastructure and factory automation.
Cognizant (CTSH) Q4 Earnings Meet Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Cognizant's (CTSH) fourth-quarter 2022 results benefit from strong digital revenues and acquisitions amid a challenging macro environment.
Apple (AAPL) Q1 Earnings Miss Estimates, Revenues Decline Y/Y
by Zacks Equity Research
Apple's (AAPL) first-quarter fiscal 2023 results reflect the supply shortage of iPhone 14 Pro and iPhone 14 Pro Max in November and through December, and a significant forex headwind.
Bruker (BRKR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Bruker (BRKR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Microchip (MCHP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Microchip's (MCHP) fiscal third-quarter results are likely to reflect robust uptake of microcontrollers, despite supply chain constraints and weak consumer end-market.
Cognizant (CTSH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Cognizant's (CTSH) fourth-quarter 2022 results are expected to reflect growing domain expertise in its digital business operations despite challenging macroeconomic conditions.
Bruker's (BRKR) New Tie-Up to Expand Its U.S. CRO Business
by Zacks Equity Research
Bruker's (BRKR) latest partnership is expected to expand its CRO business in the United States, benefiting more biopharma and diagnostics companies using unbiased proteomics for decision-making.
Are Options Traders Betting on a Big Move in Bruker (BRKR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Bruker (BRKR) stock based on the movements in the options market lately.
Bruker (BRKR) Q3 Earnings Beat Estimates, '22 Sales View Down
by Zacks Equity Research
Despite ongoing macroeconomic headwinds, Bruker (BRKR) registers strong demand for differentiated high-value scientific instruments and life science solutions.
Bruker (BRKR) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 24.53% and 4.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Bruker (BRKR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD's (BDX) New Cloud Software Solution to Boost Lab Workflow
by Zacks Equity Research
BD's (BDX) latest launch is expected to provide scientists with an integrated ecosystem that enables optimization of panel design, collaboration and analysis.
Bruker (BRKR) Gains From New Product Bookings Amid Competition
by Zacks Equity Research
Bruker's (BRKR) revenue recognition from one gigahertz class NMR system and continued uptake of the timsTOF platform hold promise.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) segmental results and robust bookings and backlog growth.
Why Is Bruker (BRKR) Down 11.3% Since Last Earnings Report?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bruker (BRKR) Debuts Innovations for Proteomics & Metabolomics
by Zacks Equity Research
Bruker's (BRKR) novel nanoElute 2 and next-generation MetaboScape 2023 release are likely to offer enhanced workflows for proteomics and metabolomics applications.
BD (BDX) Ties Up With LabCorp to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) latest partnership is expected to provide life-changing treatments for cancer and other diseases, thereby improving patient care.
Bruker (BRKR) Q2 Earnings Match Estimates, '22 Sales View Down
by Zacks Equity Research
Robust performance across the BSI and BEST segments drove Bruker's (BRKR) second-quarter top line.